ev3 Inc

ev3 — Q3 2008 Earnings Presentation

13 slides from ev3's earnings presentation, Oct 31, 2008

  1. Slide 1: Third Quarter of 2008 Highlights

    Third Quarter of 2008 Highlights October 31, 2008

  2. Slide 2: Forward-Looking Statements

    3 Forward-Looking Statements Statements contained in this press release that relate to future, not past, events are forward- looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "int

  3. Slide 3: Use of Non-GAAP Financial Measures

    5 Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation, including "net sales, excluding atherectomy and research collaboration revenues," "peripheral vascular net segment sales, excluding atherectomy revenues," "non-GAAP adjusted net income (loss)" and

  4. Slide 4: Q3 '08 Financial Achievements

    7 Q3 '08 Financial Achievements 7 Net sales of $107.0 million were up +65% vs. Q3 2007 Product sales of $100.0 were in line with previous guidance Non-GAAP adjusted net EPS* of $0.04 exceeded the high end of our guidance range by 3 cents Peripheral vascular and neurovascular net sales, excluding ath

  5. Slide 5: Actual Results vs. Last Quarter & Year Ago

    Actual Results vs. Last Quarter & Year Ago 9 Q2 2008 Actual Q3 2007 Actual $000's except EPS Net sales Gross profit Gross margin Net Loss Earnings (loss) per share Adjusted net income (loss)* Adjusted net earnings (loss) per share* $65,060 $41,963 64.5% $(36,512) $(0.60) $(30,090) $(0.50) $107,717 $

  6. Slide 6: Revenue Growth

    Revenue Growth Q4 Q1 Q2 Q3 Q3 East 92.2 101.3 107.7 65.1 107 Total Worldwide ev3 ($M) +65% Q4 Q1 Q2 Q3 Q3 East 28 34.8 35.9 26.8 36.6 Total International ($M) +37% Q4 Q1 Q2 Q3 Q3 East 57.9 64.1 70.8 38.7 66.9 (a) Excludes FoxHollow revenue Worldwide Peripheral Vascular ($M) +73% Q4 Q1 Q2 Q3 Q3 East

  7. Slide 7: Balance Sheet Highlights

    13 Balance Sheet Highlights Q3 2007 Q4 2007 Q1 2008 Q2 2008 Q3 2008 Cash, Cash Equivalents & Short Term Investments $57,136 $90,804 $57,000 $38,749 $45,947 Total Debt $10,892 $10,000 $9,107 $8,214 $9,583 Working Capital $96,950 $109,211 $107,791 $103,284 $108,568 Stockholders' Equity $303,864 $958,4

  8. Slide 8: Q3 '08 Operational Highlights

    15 Q3 '08 Operational Highlights 15 Submitted 510(k) applications to FDA EverCross and NanoCross PTA balloons Reported positive 12-month follow-up results for European DURABILITY I study, a landmark peripheral stent study covering the longest lesion lengths in a challenging patient population* Annou

  9. Slide 9: Guidance as of October 31, 2008

    17 Guidance as of October 31, 2008 Revenues: Q4 2008: $102 to $107 million Full-Year 2008: $418 to $423 million1 Adjusted EPS (loss)2 per diluted share: Q4 2008: $0.04 to $0.062,3 Full-Year 2008: $0.06 to $0.082,3 Consists of $398 to $403 million of product sales and $20.2 million of research collab

  10. Slide 10: Business Model Structure

    Business Model Structure 2008 Goal % of sales Sales 100% Gross margin 66% Selling, general & administrative 52% Taxes 0.5% Research & development 11% Stock-based comp & amortization 11% Adjusted net income (loss)* 2.0% 2007 Actual 100% 65% 69% 0.3% 17% 11% (22.4%) *Adjusted net income (loss) exclude

  11. Slide 11: Our Vital Few Projects

    Our VITAL FEW Projects Doing the Right Things Right: Our Vital Few Projects

  12. Slide 12: Leading the Way: Focus on "The Vital Few"

    Leading the Way: Focus on "The Vital Few" Improving sales productivity and operational execution Optimizing operating cost structure to achieve sustained profitability - continued reductions in SG&A Driving procedure penetration with existing and new products across both businesses Developing clinic

  13. Slide 13: Third Quarter of 2008 Highlights

    Third Quarter of 2008 Highlights October 31, 2008

ev3 — Q3 2008 Earnings Presentation on 6ix